NFA
MRSN

Nationwide Fund Advisors’s Mersana Therapeutics MRSN Stock Holding History

Nationwide Fund Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-89
Closed -$39K – 1294
2017
Q3 		$39K Buy
+89
New +$35.1K ﹤0.01% 3063

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Nationwide Fund Advisors's MRSN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2017, closing a stake of 89 shares — an estimated $39K sold.

Nationwide Fund Advisors first reported a position in MRSN in Q3 2017 and held it in 1 quarter. The position peaked at $39K in Q3 2017. 50 funds tracked by Wall St. Rank hold MRSN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Mersana Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 89 Mersana Therapeutics shares in Q4 2017, an estimated $39K.
  • Nationwide Fund Advisors first reported a position in Mersana Therapeutics in Q3 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's Mersana Therapeutics position peaked at $39K in Q3 2017.
  • 50 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.